Enochian Biosciences Inc ENOB
We take great care to ensure that the data presented and summarized in this overview for Enochian Biosciences Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENOB
View all-
Vanguard Group Inc Valley Forge, PA5.72MShares$26.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$16.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.57MShares$7.23 Million0.0% of portfolio
-
State Street Corp Boston, MA1.32MShares$6.09 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL595KShares$2.74 Million0.0% of portfolio
-
Morgan Stanley New York, NY357KShares$1.64 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA199KShares$915,2430.0% of portfolio
-
Commonwealth Equity Services, LLC102KShares$467,2350.0% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY100KShares$459,9990.04% of portfolio
-
Jpmorgan Chase & CO New York, NY93KShares$427,8450.0% of portfolio
Latest Institutional Activity in ENOB
Top Purchases
Top Sells
About ENOB
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Insider Transactions at ENOB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 14
2024
|
David Hershel Weinstein Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Aug 23
2024
|
Avram Miller Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
833,333
-83.33%
|
-
|
|
Aug 12
2024
|
Karen Brink Director |
SELL
Other acquisition or disposition
|
Indirect |
2,000,000
-7.88%
|
-
|
|
Jul 29
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
1,114
-0.13%
|
$1,114
$1.3 P/Share
|
|
Jul 17
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
16,362
-1.91%
|
$16,362
$1.46 P/Share
|
|
Jul 15
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
21,954
-2.45%
|
$21,954
$1.41 P/Share
|
|
Jul 11
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
14,896
-1.63%
|
$14,896
$1.51 P/Share
|
|
Jul 10
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
75,000
-7.73%
|
$75,000
$1.51 P/Share
|
|
Jul 09
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
4,630
-0.48%
|
$4,630
$1.53 P/Share
|
|
Jul 05
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
60,000
-5.8%
|
$60,000
$1.55 P/Share
|
|
Jul 03
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
50,000
-4.61%
|
$50,000
$1.51 P/Share
|
|
Jul 02
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
34,553
-3.09%
|
$34,553
$1.54 P/Share
|
|
Jul 01
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
60,000
-5.09%
|
$60,000
$1.56 P/Share
|
|
Jun 27
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
14,671
-1.23%
|
$14,671
$1.5 P/Share
|
|
Jun 26
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
50,000
-4.02%
|
$50,000
$1.57 P/Share
|
|
Jun 25
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
20,000
-1.58%
|
$20,000
$1.58 P/Share
|
|
Jun 14
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
50,000
-3.81%
|
$50,000
$1.58 P/Share
|
|
Jun 06
2024
|
Karen Brink Director |
SELL
Other acquisition or disposition
|
Indirect |
1,853,517
-6.81%
|
-
|
|
Feb 20
2024
|
Rene Sindlev Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
471,699
+3.35%
|
$0
$0.53 P/Share
|
|
Feb 13
2024
|
Ole Abildgaard > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,436,190
+30.32%
|
-
|
Last 12 Months Summary
| Conversion of derivative security | 4.14M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 472K shares |
| Grant, award, or other acquisition | 250K shares |
| Open market or private sale | 473K shares |
|---|---|
| Sale (or disposition) back to the issuer | 833K shares |
| Other acquisition or disposition | 3.85M shares |